腫瘍学と免疫学におけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、競合、機会、予測、タイプ別、技術別、提供サービス別、用途別、エンドユーザー別、地域別、競合別セグメント、2020-2030年

世界の腫瘍学と免疫学におけるフローサイトメトリー市場は、2024年に34億1,000万米ドルと評価され、2030年には54億7,000万米ドルに達すると予測され、予測期間中のCAGRは8.19%で成長します。

市場成長は、高度なフローサイトメーターの進化とともに、がんや免疫学研究におけるフローサイトメトリーの有用性が高まっていることが後押ししています。がんが世界の死因の上位にランクされ、免疫腫瘍学が重要な学問分野として台頭していることから、高精度の診断・モニタリングツールに対する需要が高まっています。フローサイトメトリーは、様々なサンプルタイプにおける細胞特性、免疫マーカー、腫瘍抗原の評価に不可欠なものとなっています。次世代フローサイトメトリーツールは、特に免疫療法や個別化治療の臨床試験において、治療モニタリングや診断と統合され、世界の普及を後押ししています。研究投資の増加や疾病の早期発見の世界の重視と相まって、これらの要因は総体的に腫瘍学と免疫学の両分野におけるフローサイトメトリーの範囲と応用を拡大しています。

市場促進要因

がん罹患率の上昇が診断需要を牽引

主な市場課題

高コストと運用の複雑さ

主な市場動向

人工知能および機械学習との統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の腫瘍学と免疫学におけるフローサイトメトリー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（免疫学、腫瘍学）
  • 技術別（細胞ベースフローサイトメトリー、ビーズベースフローサイトメトリー）
  • 提供内容別（試薬、機器、消耗品、ソフトウェア）
  • 用途別（トランスレーショナル調査、臨床調査）
  • エンドユーザー別（病院、診断研究所、基準研究所、製薬・バイオテクノロジー企業、学術調査機関、契約調査機関など）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024）
• 市場マップ
  • タイプ別
  • 技術別
  • 提供別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 北米の腫瘍学と免疫学におけるフローサイトメトリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の腫瘍学と免疫学におけるフローサイトメトリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の腫瘍学と免疫学におけるフローサイトメトリー市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米の腫瘍学と免疫学におけるフローサイトメトリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの腫瘍学と免疫学におけるフローサイトメトリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威/サービス

第14章 世界の腫瘍学と免疫学におけるフローサイトメトリー市場：SWOT分析

第15章 競合情勢

• Danaher Corporation
• Merck KGaA
• Miltenyi Biotec
• Neo-Genomics Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Cell Signaling Technology, Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• DiaSorin S.p.A
• OPKO Health, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Flow Cytometry in Oncology and Immunology Market was valued at USD 3.41 billion in 2024 and is projected to reach USD 5.47 billion by 2030, growing at a CAGR of 8.19% during the forecast period. Market growth is propelled by the increasing utility of flow cytometry in cancer and immunology research, alongside the evolution of advanced flow cytometers. With cancer ranking among the leading causes of death globally, and immuno-oncology gaining ground as a crucial discipline, there is rising demand for high-precision diagnostic and monitoring tools. Flow cytometry has become indispensable in evaluating cell characteristics, immune markers, and tumor antigens across various sample types. The integration of next-generation flow cytometry tools with therapeutic monitoring and diagnostics, especially in clinical trials for immunotherapies and personalized treatments, is boosting global adoption. Combined with rising research investments and the global emphasis on early disease detection, these factors are collectively expanding the reach and application of flow cytometry in both oncology and immunology.

Key Market Drivers

Rising Cancer Incidence Driving Diagnostic Demand

The growing global cancer burden is a key driver for the adoption of flow cytometry in oncology diagnostics. This technique is critical for diagnosing and monitoring blood cancers like leukemia and lymphoma, enabling precise cellular analysis and biomarker identification. As per WHO, cancer accounted for nearly 10 million deaths in 2020, and GLOBOCAN estimates that new cancer cases will surge past 28 million by 2040. Flow cytometry is also instrumental in detecting minimal residual disease (MRD) and supporting treatment decisions. With increasing adoption of immunotherapies and personalized oncology treatments, flow cytometry's role in immune profiling and response monitoring is expanding. In support, organizations like the U.S. National Cancer Institute have committed billions to precision medicine and diagnostics infrastructure, fostering widespread implementation. These efforts underscore flow cytometry's importance in the future of cancer diagnosis and treatment.

Key Market Challenges

High Cost and Operational Complexity

Despite its clinical and research value, flow cytometry adoption is hindered by high operational and capital expenses. The cost of acquiring high-end instruments, software, and consumables is substantial, making it challenging for institutions in developing regions to invest. Additionally, flow cytometry requires technical expertise for calibration, analysis, and interpretation-skills that are often limited in resource-constrained settings. Complex data interpretation can introduce variability and errors, further complicating implementation. The lack of infrastructure and diagnostic capacity in many low- and middle-income countries reinforces disparities in access to this technology. According to WHO data, these regions have significantly fewer diagnostic labs per capita, highlighting access challenges. Addressing these cost and skill barriers is essential to ensuring broader and more equitable utilization of flow cytometry worldwide.

Key Market Trends

Integration with Artificial Intelligence and Machine Learning

A transformative trend in the flow cytometry space is the integration of artificial intelligence (AI) and machine learning (ML) into data processing workflows. Traditional manual gating and analysis can be time-consuming and prone to human error. AI and ML technologies now streamline these processes by automating gating, improving pattern recognition, and extracting high-dimensional insights from complex datasets. In oncology, ML algorithms are being applied to predict treatment outcomes using immune signatures from flow cytometry data. In immunology, these tools aid in identifying rare cell subsets and monitoring immune dynamics with high precision. Global research initiatives like NIH's Bridge2AI and the EU's Horizon Europe are actively funding the incorporation of AI into diagnostics, including flow cytometry. This convergence of data science with laboratory medicine is poised to elevate accuracy, reproducibility, and clinical utility, marking a pivotal evolution in how flow cytometry is applied in healthcare.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Miltenyi Biotec
• Neo-Genomics Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Cell Signaling Technology, Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• DiaSorin S.p.A
• OPKO Health, Inc.

Report Scope:

In this report, the Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

• Immunology
• Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

• Cell-based flow cytometry
• Bead-based flow cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

• Reagents
• Instruments
• Consumables
• Software

Flow Cytometry in Oncology and Immunology Market, By Application:

• Translational Research
• Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

• Hospitals
• Diagnostic Laboratories
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others

Flow Cytometry in Oncology and Immunology Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations:

Global Flow Cytometry in Oncology and Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Immunology, Oncology)
  • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
  • 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
  • 5.2.4. By Application (Translational Research, Clinical Research)
  • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
  • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Type
  • 5.3.2. By Technology
  • 5.3.3. By Offering
  • 5.3.4. By Application
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Technology
  • 6.2.3. By Offering
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Offering
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Offering
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Offering
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Technology
  • 7.2.3. By Offering
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Offering
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Offering
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Offering
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Offering
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Offering
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Technology
  • 8.2.3. By Offering
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Offering
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Offering
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Offering
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Offering
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Offering
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Flow Cytometry in Oncology and Immunology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Technology
  • 9.2.3. By Offering
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Offering
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Offering
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Offering
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Technology
  • 10.2.3. By Offering
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Offering
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Offering
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Offering
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challanges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. Global Flow Cytometry in Oncology and Immunology Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Miltenyi Biotec
• 15.4. Neo-Genomics Laboratories, Inc.
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. Cell Signaling Technology, Inc.
• 15.7. Becton, Dickinson and Company
• 15.8. Agilent Technologies, Inc.
• 15.9. DiaSorin S.p.A
• 15.10. OPKO Health, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer